The anti-amyloidogenic effect is exerted against Alzheimer's β-amyloid fibrils in vitro by preferential and reversible binding of flavonoids to the amyloid fibril structure

被引:142
作者
Hirohata, Mie
Hasegawa, Kazuhiro
Tsutsumi-Yasuhara, Shinobu
Ohhashi, Yumiko
Ookoshi, Tadakazu
Ono, Kenjiro
Yamada, Masahito
Naiki, Hironobu [1 ]
机构
[1] Univ Fukui, Fac Med Sci, Dept Pathol Sci, Div Mol Pathol, Fukui 9101193, Japan
[2] Kanazawa Univ, Grad Sch Med Sci, Dept Neurol & Neurobiol Aging, Kanazawa, Ishikawa 9208640, Japan
关键词
D O I
10.1021/bi061540x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
How various anti-amyloidogenic compounds inhibit the formation of Alzheimer's beta-amyloid fibrils (fA beta) from amyloid beta-peptide (A beta) and destabilize fA beta remains poorly understood. Using spectrophotometry, spectrofluorometry, atomic force microscopy, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and surface plasmon resonance (SPR), we investigated the anti-amyloidogenic effects of five flavonoids on fA beta in vitro. Oxidized flavonoids generally inhibited fA beta(1-40) formation significantly more potently than fresh compounds. Characterization of the novel fluorescence of myricetin (Myr) emitted at 575 nm with an excitation maximum at 430 nm in the presence of fA beta(1-40) revealed the specific binding of Myr to fA beta(1-40). By SPR analysis, distinct association and dissociation reactions of Myr with fA beta(1-40) were observed, in contrast to the very weak binding to the A beta monomer. A significant decrease in the rate of fibril extension was observed when > 0.5 mu M Myr was injected into the SPR experimental system. These findings suggest that flavonoids, especially Myr, exert an anti-amyloidogenic effect in vitro by preferentially and reversibly binding to the amyloid fibril structure of fA beta, rather than to A beta monomers.
引用
收藏
页码:1888 / 1899
页数:12
相关论文
共 44 条
[1]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[2]   Affinity-based inhibition of β-amyloid toxicity [J].
Cairo, CW ;
Strzelec, A ;
Murphy, RM ;
Kiessling, LL .
BIOCHEMISTRY, 2002, 41 (27) :8620-8629
[3]   Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice [J].
Cherny, RA ;
Atwood, CS ;
Xilinas, ME ;
Gray, DN ;
Jones, WD ;
McLean, CA ;
Barnham, KJ ;
Volitakis, I ;
Fraser, FW ;
Kim, YS ;
Huang, XD ;
Goldstein, LE ;
Moir, RD ;
Lim, JT ;
Beyreuther, K ;
Zheng, H ;
Tanzi, RE ;
Masters, CL ;
Bush, AI .
NEURON, 2001, 30 (03) :665-676
[4]   Kinetic stabilization of the α-synuclein protofibril by a dopamine-α-synuclein adduct [J].
Conway, KA ;
Rochet, JC ;
Bieganski, RM ;
Lansbury, PT .
SCIENCE, 2001, 294 (5545) :1346-1349
[5]  
Dangles O, 2001, METHOD ENZYMOL, V335, P319
[6]   One-electron oxidation of quercetin and quercetin derivatives in protic and non protic media [J].
Dangles, O ;
Fargeix, G ;
Dufour, C .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1999, (07) :1387-1395
[7]   Practice parameter: Management of dementia (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology [J].
Doody, RS ;
Stevens, JC ;
Beck, C ;
Dubinsky, RM ;
Kaye, JA ;
Gwyther, L ;
Mohs, RC ;
Thal, LJ ;
Whitehouse, PJ ;
DeKosky, ST ;
Cummings, JL .
NEUROLOGY, 2001, 56 (09) :1154-1166
[8]   Anti-amyloidogenic activity of tetracyclines: studies in vitro [J].
Forloni, G ;
Colombo, L ;
Girola, L ;
Tagliavini, F ;
Salmona, M .
FEBS LETTERS, 2001, 487 (03) :404-407
[9]   Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels [J].
Frostell-Karlsson, Å ;
Remaeus, A ;
Roos, H ;
Andersson, K ;
Borg, P ;
Hämäläinen, M ;
Karlsson, R .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (10) :1986-1992
[10]   Medicine - The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics [J].
Hardy, J ;
Selkoe, DJ .
SCIENCE, 2002, 297 (5580) :353-356